500 MW Solar Plant Approved

Source: Renewable Energy World (11/17/10)

"The Amargosa Farm Road Solar Project is the second plant approved for public lands in Nevada.

Secretary of the Interior Ken Salazar this week approved the construction of yet another large-scale solar energy project on U.S. public lands. This one, the Amargosa Farm Road Solar Project will be built in Nevada and is the second plant approved for public lands in that state.

Solar Millennium will develop the 500-megawatt facility that will use concentrated solar power (CSP) technology to collect solar energy from two 250-MW parabolic troughs and use dry-cooled power plants equipped with thermal energy storage capability.

According to the Department of the Interior (DOI), the project has undergone extensive environmental review, starting with public scoping and followed by a draft environmental impact statement with full public involvement and a final Environmental Impact Statement that was published on October 15.

DOI said that the BLM, U.S. Fish and Wildlife Service, and National Park Service worked closely with Solar Millennium to develop a water mitigation plan that they hope will serve as a model for future solar projects. The plan is said to ensure that the project will have a net neutral benefit on the plant and animal species found at nearby Ash Meadows National Wildlife Refuge and Devils Hole.

The BLM also worked with Solar Millennium to reduce the approved project footprint from 7,630 acres to 6,320 acres with a disturbance area of 4,350 acres, according to DOI. BLM will require a natural color palette and minimum night lighting measures to reduce visual impacts on the local community.

Through the ARRA, Solar Millennium is eligible for approximately $1 billion in Investment Tax credits. The company is also eligible to apply for financing through the DOE Title 17 Loan Guarantee Program. The company is in PPA negotiations with NV Energy to sell the electricity generated by the plant to the utility.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.